Literature DB >> 12421356

TorsinA and heat shock proteins act as molecular chaperones: suppression of alpha-synuclein aggregation.

Pamela J McLean1, Hibiki Kawamata, Saadat Shariff, Jeffrey Hewett, Nutan Sharma, Kenji Ueda, Xandra O Breakefield, Bradley T Hyman.   

Abstract

TorsinA, a protein with homology to yeast heat shock protein104, has previously been demonstrated to colocalize with alpha-synuclein in Lewy bodies, the pathological hallmark of Parkinson's disease. Heat shock proteins are a family of chaperones that are both constitutively expressed and induced by stressors, and that serve essential functions for protein refolding and/or degradation. Here, we demonstrate that, like torsinA, specific molecular chaperone heat shock proteins colocalize with alpha-synuclein in Lewy bodies. In addition, using a cellular model of alpha-synuclein aggregation, we demonstrate that torsinA and specific heat shock protein molecular chaperones colocalize with alpha-synuclein immunopositive inclusions. Further, overexpression of torsinA and specific heat shock proteins suppress alpha-synuclein aggregation in this cellular model, whereas mutant torsinA has no effect. These data suggest that torsinA has chaperone-like activity and that the disease-associated GAG deletion mutant has a loss-of-function phenotype. Moreover, these data support a role for chaperone proteins, including torsinA and heat shock proteins, in cellular responses to neurodegenerative inclusions.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12421356     DOI: 10.1046/j.1471-4159.2002.01190.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  117 in total

Review 1.  The Lewy body in Parkinson's disease and related neurodegenerative disorders.

Authors:  Koichi Wakabayashi; Kunikazu Tanji; Saori Odagiri; Yasuo Miki; Fumiaki Mori; Hitoshi Takahashi
Journal:  Mol Neurobiol       Date:  2012-05-24       Impact factor: 5.590

Review 2.  Drug targets from genetics: α-synuclein.

Authors:  Karin M Danzer; Pamela J McLean
Journal:  CNS Neurol Disord Drug Targets       Date:  2011-09-01       Impact factor: 4.388

Review 3.  Torsins: not your typical AAA+ ATPases.

Authors:  April E Rose; Rebecca S H Brown; Christian Schlieker
Journal:  Crit Rev Biochem Mol Biol       Date:  2015-10-13       Impact factor: 8.250

Review 4.  Molecular chaperones in Parkinson's disease--present and future.

Authors:  Darius Ebrahimi-Fakhari; Lara Wahlster; Pamela J McLean
Journal:  J Parkinsons Dis       Date:  2011       Impact factor: 5.568

5.  Insights into the domains required for dimerization and assembly of human alphaB crystallin.

Authors:  Joy G Ghosh; John I Clark
Journal:  Protein Sci       Date:  2005-03       Impact factor: 6.725

6.  Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases.

Authors:  Ruth A Bodner; Tiago Fleming Outeiro; Stephen Altmann; Michele M Maxwell; Stephanie H Cho; Bradley T Hyman; Pamela J McLean; Anne B Young; David E Housman; Aleksey G Kazantsev
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-06       Impact factor: 11.205

Review 7.  Challenging Proteostasis: Role of the Chaperone Network to Control Aggregation-Prone Proteins in Human Disease.

Authors:  Tessa Sinnige; Anan Yu; Richard I Morimoto
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

Review 8.  Association of heat-shock proteins in various neurodegenerative disorders: is it a master key to open the therapeutic door?

Authors:  Subhankar Paul; Sailendra Mahanta
Journal:  Mol Cell Biochem       Date:  2013-10-05       Impact factor: 3.396

Review 9.  Expanding role of molecular chaperones in regulating α-synuclein misfolding; implications in Parkinson's disease.

Authors:  Sandeep K Sharma; Smriti Priya
Journal:  Cell Mol Life Sci       Date:  2016-08-13       Impact factor: 9.261

10.  Dominant-positive HSF1 decreases alpha-synuclein level and alpha-synuclein-induced toxicity.

Authors:  Xu Liangliang; Hou Yonghui; E Shunmei; Gong Shoufang; Zhou Wei; Zou Jiangying
Journal:  Mol Biol Rep       Date:  2009-07-17       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.